Supreme Court Gene Ruling Has Silver Lining for BioTime

By Patrick CoxPosted June 18, 2013

Whenever the Supreme Court hands down a ruling on some company's patent claim to a gene, markets tend to react, as investors worry about possibly far-reaching consequences. This isn't, of course, surprising. The science behind gene patents is complicated. Biotech patent law is just as confusing, but is even more inscrutable because it is decided by humans, rather than nature. At stake are thousands of gene patents.

You Must Be A Subscriber To View This Content.

If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!

Breakthrough Technology Alert

This is the best time to be investing in world-changing technologies, as unprecedented innovations are taking off right now… Breakthrough Technology Alert tirelessly researches these exciting new breakthrough technologies to keep you well informed, outline specific opportunities, and keep you ahead of the game.

Patrick Cox

Patrick Cox has lived deep inside transformative technologies for over 25 years. In the 1980s, he worked in software development and manufacturing. By the mid-‘90s, he consulted for Netscape–which handled 90% of all Internet browsing traffic at the time. InfoWorld and USA Today have featured his research, and he’s written for The Wall Street Journal,...

View More By Patrick Cox

More on Aura Systems, Arrowhead and BioTime

By Patrick CoxPosted September 20, 2011

Efforts to raise the cost of traditional energy sources were part of this plan. We've heard, for example, certain well-placed politicians and activists brag that they would like to see energy at twice current costs. This bizarre sentiment is evidence, however, of either gross economic illiteracy or sociopathic tendencies.

Important Updates On Three Of Our Favorite Companies

By Ray BlancoPosted September 17, 2013

I'm just about to send your next issue to the editors. It's almost ready. I have a company bringing a new twist to an old technology -- and bringing hope of dealing with the spiraling crisis of resistant bacteria. Thanks to recent legislation, the regulatory burden of developing drugs to deal with this problem has been somewhat eased, and private innovators are rushing to fill an urgent market need. I don't want to say much more right now or I might give it away, but you'll find out about it really soon.

A (No Rush) Sell Order & a Review of BioTime’s Cardiovascular Therapy

By Patrick CoxPosted January 18, 2011

I'm going to issue a sell order today, but I want to clarify that it is not because I don't think the company will continue to go up. I think it will. Rather, it is because the company has changed and is no longer involved in the cutting-edge nanotech research it was doing when we acquired it.

Lilly Halts Alzheimer’s Drug Test — As Predicted

By Patrick CoxPosted August 24, 2010

Eli Lilly has stopped human testing of Semagacestat. This is big news. In fact, it is potentially great news for one of our companies. Of course, if you've been reading this publication for a while, you won't be surprised.

60% Gains for Our 5G Play!

By Ray BlancoPosted January 12, 2021

Good news is sending our 5G plays soaring! As 5G networks deploy, the devices that operate on them require more complex and higher-fidelity communications circuits. And there’s good reason to expect the company to keep growing in 2021!

Inovio’s HIV Drug Works in Monkeys & Anavex Named “Most Promising” AD Candidate

By Patrick CoxPosted January 11, 2011

It's been a big couple of weeks. Enormous economic, scientific and sociological trend lines are coming into focus. And I've got to admit that I'm feeling better than I have in years about our future. I'm still dealing with last week's news that Dr. Michael West is going to commercialize endothelial precursor stem cell therapy. His ability to restore the heart, vascular and immune systems to full youthful health, using the donors' own cells, has so many enormous implications. Few at this point get it.